丹麦全国性研究:含邻苯二甲酸酯药品的累积暴露量
该研究基于丹麦全国处方登记库和药品管理局内部数据库,量化了2004-2016年间使用含邻苯二甲酸酯口服药品的丹麦人群年度累积暴露量。结果显示暴露人数下降,但暴露者的邻苯二甲酸二丁酯中位年暴露量仍高于欧洲监管限值(380-1710 mg/年),锂产品是主要来源;邻苯二甲酸二乙酯暴露未超限。
要点
- 暴露者邻苯二甲酸二丁酯中位年暴露量全程高于欧洲监管限值(380-1710 mg/年)。
- 锂产品是邻苯二甲酸二丁酯暴露的主要来源,二乙酯暴露未超EMA限值。
核心结论
- 2004-2016年丹麦含邻苯二甲酸酯口服药品暴露人数下降,但使用仍相当可观。
- 暴露者的邻苯二甲酸二丁酯中位年暴露量持续高于欧洲监管限值。
研究设计与样本
- 丹麦全国性队列研究,使用丹麦全国处方登记库和丹麦药品管理局内部数据库,覆盖2004-2016年。
主要发现
- 暴露者邻苯二甲酸二丁酯中位年暴露量全程高于欧洲监管限值(380-1710 mg/年)。
- 锂产品构成邻苯二甲酸二丁酯暴露的大部分。
- 邻苯二甲酸二乙酯暴露主要来自红霉素、茶碱和双氯芬酸产品,未超过EMA监管限值。
关键数值与推荐
- 欧洲监管限值:邻苯二甲酸二丁酯暴露限值范围为380-1710 mg/年。
临床怎么用
- 临床药师应关注含邻苯二甲酸酯辅料药品的长期使用,尤其是锂产品。
- 对需长期使用含邻苯二甲酸二丁酯药品的患者,可评估替代方案以降低累积暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Up to 50-fold higher levels of urinary phthalate metabolites have been observed in users of phthalate-containing drug products compared with non-users. This is of concern, as phthalates are suspected endocrine disrupters and have been associated with cancer development. This study aims to quantify annual cumulated phthalate exposure from drug products among users of phthalate-containing oral medications in Denmark throughout the period of 2004-2016. METHODS: We conducted a Danish nationwide cohort study using The Danish National Prescription Registry and an internal database held by The Danish Medicines Agency. These databases hold information on drug products; date of dispensing, and the type and quantity of excipients in drugs with Danish marketing permission. We present the number of users over time and their distribution of exposure to enteric phthalate polymers and ortho-phthalates. RESULTS: The annual number of individuals exposed to phthalate-containing products declined during 2004-2016. The total number of individuals exposed to dibutyl phthalate declined from 21 499 in 2004 to 5400 in 2016. However, among those exposed, the median dibutyl phthalate exposure remained above European regulatory limit of exposure ranging between 380-1710 mg/year throughout the study period. Lithium-products constituted the majority of dibutyl phthalate exposure. Diethyl phthalate exposure, mainly caused by erythromycin, theophylline and diclofenac products, did not exceed the EMA regulatory limit. CONCLUSION: While the number of individuals exposed to phthalates from oral medications during 2004-2016 declined, the use of phthalate-containing drugs is still considerable.
引用
- Ennis ZN, Broe A, Pottegård A, et al. Cumulative exposure to phthalates from phthalate-containing drug products: a Danish population-wide study. Br J Clin Pharmacol. 2018. PMID: 29688578. doi:10.1111/bcp.13614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。